Google AI for Health Program Selects Five African Startups

By HEOR Staff Writer

October 26, 2023

A New Era for African Health Startups

The 2023 cohort of the Google for Startups Growth Academy: AI for Health program has been announced. The aforementioned selection comprises a total of 30 startup companies. All originating from the regions of Europe, the Middle East, and Africa. Out of the selection, five African firms have been designated, namely mDoc and PharmaRun from Nigeria.

The selection of these firms is based on their utilization of artificial intelligence (AI) in a pioneering manner to address health-related obstacles. They have the potential to enhance healthcare by implementing artificial intelligence (AI)-based solutions. This encompasses a wide range of areas, spanning from the early diagnosis of diseases to the promotion of universal access to information.

 

The Conceptual Framework Underlying the Program

Yuval Passov, the Head of Google for entrepreneurs, articulated his perspective on the potential of African health entrepreneurs utilizing artificial intelligence (AI). The author found Africa’s pioneering attitude in the field of AI for Health to be highly motivating. The chosen startups serve as evidence of the continent’s capacity to create worldwide health solutions. Google’s objective is to align itself with these entities, providing assistance and collaboration as they endeavor to expand and distribute their innovative solutions.

The Google for businesses Growth Academy: AI for Health program aligns with Google’s goal to help businesses grow faster. This program aims to support selected African and international companies. It strives to encourage innovation and healthcare advancements. Ultimately, it seeks to create a lasting positive impact on global welfare.

Reference url

Recent Posts

Accelerating Tec-Dara Multiple Myeloma Therapy Review: A Game Changer for Patients

By HEOR Staff Writer

December 16, 2025

Accelerating Review for Transformative Multiple Myeloma Therapy The U.S. Food and Drug Administration (
CHMP Meeting Highlights: December 2025 Advances in New Medicines Approvals
The CHMP meeting highlights from December 2025 reveal major advancements in drug approvals. What were the key outcomes of the EMA's Committee for Medicinal Products for Human Use session held December 8-11? The committee recommended seven new medicines for approval. These target critical areas li...
AKEEGA BRCA2 Approval: Landmark FDA Decision for Precision Therapy in Aggressive Prostate Cancer
AKEEGA BRCA2 Approval Ushers in Precision Era for mCSPC The AKEEGA BRCA2 approval by the U.S. Food and Drug Administration (FDA) on December 12, 2025, represents a breakthrough for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC). Johnson & Johnson...